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Introduction
Cardiovascular disease (CVD) is the leading cause of mor-
tality and morbidity in diabetic patients (1). In diabetes mel-
litus (DM), obstructive coronary artery disease (CAD) is more 
common, and diabetic patients have more extensive disease 
than patients with other risk factors for CAD (2). Thus, it has 
clinical importance to find out simple and robust biomarkers 
that predict the presence and severity of CAD in this high-risk 
population.
Neutrophil gelatinase-associated lipocalin (NGAL) belongs 
to the lipocalin superfamily of proteins that accumulate in gran-
ules of neutrophils (3). It has been demonstrated to be released 
in case of renal tubular damage due to ischemia and/or neph-
rotoxins and suggested as an early marker of acute kidney in-
jury (4). Furthermore, NGAL is expressed in endothelial cells 
and macrophages in atherosclerotic plaques (5). It enhances 
the activity of matrix metalloproteinase-9, which plays important 
role in plaque instability (6). NGAL modulates inflammation and 
promotes development and progression of atherosclerosis (3–6). 
Previously, serum NGAL levels have been shown to be associ-
ated with the extent of stable CAD (7) and to be elevated in acute 
coronary syndromes (8). However, despite the putative role of 
inflammation in pathogenesis of type 2 DM and CVD (9, 10), NGAL 
has not yet been elucidated in predicting the severity of CAD in 
diabetic patients.
Cystatin C is a low-molecular-weight (13kD) protein be-
longing to the cystatin super- family of cysteine proteinase 
inhibitors. It is synthesized by all nucleated cells, filtered from 
glomeruli, and is almost completely reabsorbed by proximal 
renal tubules (11). When compared to serum creatinine, it is 
less influenced by age, gender, race, muscle mass, exercise, 
and diet. Therefore, serum cystatin C is accepted as a superior 
blood parameter than creatinine clearance for estimating renal 
functions (12). Cystatin C has been shown to be related with 
increased coronary atherosclerotic burden (13, 14), probably 
due to contribution to inflammatory processes. Inflammatory 
cytokines stimulate the production of lysosomal cathepsins, 
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which degrade extracellular matrix proteins; and concentration 
of cystatin C, a cathepsin inhibitor, is elevated to counterbal-
ance this elastolytic overactivity (15). In metabolic syndrome, 
cystatin C has been found to be associated with severity of CAD 
(16). However, there are limited data evaluating this association 
in diabetic population.
We argued that these biomarkers could reflect the increased 
inflammatory status in diabetic coronary atherosclerosis. Ac-
cordingly, in the present study, we aimed to determine serum 
cystatin C and NGAL levels for predicting the severity of CAD in 
diabetic patients.
Methods
Study population
This was a single-center, prospective, cross-sectional 
study. Power analysis of the study was performed using the 
program of G*Power power-and-sample size calculation Ver-
sion 3.1.9.2. Düsseldorf Universität, Germany (17). Accordingly, 
with an alpha error value of 0.05 and Cohen’s effect size of 0.8 
and power of 0.80, the projected sample size was found to be 52 
subjects for the inferential statistics (t tests-means: difference 
between two independent groups). The study was conducted 
in accordance with the guidelines proposed in the Helsinki 
Declaration and approved by Başkent University Institutional 
Review Board and supported by Başkent University Scientific 
Research Fund. All the participants gave written informed con-
sent before enrollment. 
The subjects were consecutive type 2 diabetic patients who 
underwent elective CAG due to suspected diagnosis of stable 
CAD in our institute. Patients with a serum creatinine of >1.4 mg/
dL for men and >1.2 mg/dL for women and/or with an estimat-
ed glomerular fi ltration rate (eGFR) <60 mL/min/1.73 m2, active 
or chronic liver diseases, active infectious conditions, chronic 
inflammatory or rheumatological diseases, and malignancies 
were not included. Also, patients with unstable angina, conges-
tive heart failure, severe valvular disorders, and history of prior 
percutaneous coronary intervention /coronary artery by-pass 
graft operation were not included. Fifty-two eligible type 2 dia-
betic patients were analyzed. 
Weight and height of the patients were measured without 
heavy outer garments and shoes, after a 12-hour fasting peri-
od. Office blood pressure was measured two times on the right 
arm in the sitting position, with a 5-min interval, and the average 
value was used. Hypertension was accepted as systolic blood 
pressure ≥140 mm Hg; diastolic blood pressure, ≥90 mm Hg, or 
being treated with anti-hypertensive medication. Diabetes mel-
litus was defined as being treated with anti-diabetic medica-
tions (oral anti-diabetics / insulin). Smoking was defined as the 
regular use of tobacco. Hyperlipidemia was defined as having 
total cholesterol level >200 mg/dL or use of hypolipidemic medi-
cations. eGFR was calculated by Modification of Diet in Renal 
Disease (MDRD) equation (18). 
Laboratory measurements
The venous blood samples for routine laboratory measure-
ments were taken after 12-hours overnight fasting within 72 
hours prior to CAG and analyzed in 1 hour. For determination 
of cystatin C and NGAL levels, the venous blood samples were 
drawn on the morning of CAG and stored at −20°C until analysis 
time, and were detected with sandwich enzyme immunoassay 
method using commercial Human Cystatin C kits (Biovendor 
Laboratory Medicine Inc., Brno, Czech Republic) and Human 
Lipocalin-2/NGAL kits (Biovendor Laboratory Medicine Inc.), re-
spectively, by a microelisa analyser device (DSX Model; Dynex 
Technologies, Chantilly, VA, USA).
Coronary angiography
The coronary angiographies were performed using the stan-
dard Judkins technique. The angiograms were reviewed by two 
independent experienced invasive cardiologists for the presence 
and severity of CAD. Coronary vessel score was ranged between 
0 and 3 according to the number of the main coronary arteries—
left anterior descending (LAD), left circumflex (Cx), and right cor-
onary artery (RCA)—with a ≥50% stenosis. Significant CAD was 
defined as a vessel score ≥1. Gensini score (19) was calculated 
for evaluation of the CAD severity in each patient. This system 
scores the stenosis in the epicardial coronary arteries (1 point 
for 1–25% stenosis, 2 for 26–50% stenosis, 4 for 51–75% stenosis, 
8 for 76–90% stenosis, 16 for 91–99% stenosis, and 32 for total 
occlusion) and multiplies this number by a constant number in 
term of the anatomical position of the lesion. Multipliers are 5 for 
the left main coronary artery; 2.5 for the proximal segment of the 
LAD and Cx; 1.5 for the mid-segment of the LAD; 1 for the RCA, 
the distal segment of the LAD, the posterolateral artery, and the 
obtuse marginal artery; and 0.5 for other segments. The score in 
every segment is calculated, and the total score gives the Gensi-
ni score. The patients who have history of coronary revascular-
ization (percutaneous coronary intervention or coronary artery 
bypass graft operation) were excluded from the study since the 
original Gensini’s scoring system is technically inappropriate for 
such cases. The median Gensini score was 23 (5–51, IQR: 46). 
The patients were divided into groups of severe and non-severe 
CAD according to this median score.
Statistical analysis 
The normality of distribution was tested using Kolmogorov–
Smirnov test. Continuous variables were presented as mean±SD 
if normally distributed otherwise as median with 25th and 75th per-
centiles. Categorical variables were presented as numbers and 
percentages and were compared using chi-square test (Fisher’s 
exact test if needed). Student’s t-test or Mann–Whitney U test 
was used for comparison of continuous variables where ap-
propriate. Correlation analysis was performed using Spearman 
test. A multiple linear regression analysis model was generated 
in order to investigate the independent predictors of the Gensini 
score. Receiver operating characteristic (ROC) analysis was 
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used to predict the cut off points for cystatin C in determination 
of multi-vessel disease. Then, sensitivity and specificity were 
calculated. Statistical analysis was performed by SPSS software 
(version 17; Statistical Package for Social Sciences, Chicago, IL). 
A p value of <0.05 was considered statistically significant.
Results
The mean age of the study population (20 females and 32 
males) was 65.7±8.6 years. The clinical data and demographic 
features of the entire study population are presented in Table 1. 
The patients were divided into subgroups of severe and non-se-
vere CAD. Patients with higher Gensini score had higher serum 
creatinine and lower eGFR values compared with those having 
lower Gensini score. Other parameters were similar in regard to 
groups arranged with Gensini score (Table 1). 
There was a trend toward higher cystatin C levels in patients 
with significant CAD (n=34) than in those without (n=18) [1101 
(908–1378) vs. 915 (569–1162), respectively, p=0.09]. Regarding 
the patients with significant CAD, serum cystatin C levels were 
found to be higher in patients with multivessel disease (n=18) 
than in those with single vessel disease (n=16) [1260 ng/mL 
(953–1640) vs. 977 ng/mL (599–1114), respectively, p=0.017]. Se-
rum cystatin C concentrations were increased across the vessel 
score [0 vessel, n=18: 915 ng/mL (569–1162); single vessel, n=16: 
977 ng/mL (599–1114); two vessels, n=8: 1199 ng/mL (915–1476); 
and three vessels, n=10: 1393ng/mL (967–1724); p=0.03] (Fig. 1). 
The patients with higher Gensini score had also higher cys-
tatin C levels than those with lower Gensini score [1114 ng/mL 
(948–1567) vs. 929 ng/mL (569–1156), respectively, p=0.009]. In all 
of the above-mentioned subgroups, there were no differences 
in serum NGAL levels (Table 2 summarizes cystatin C and NGAL 
levels compared between the groups).
Cystatin C levels were positively correlated with Gensini 
score (r=0.334, p=0.016), and serum creatinine levels (r=0.501, 
p<0.001), and negatively with eGFR value (r=0.479, p<0.001). Mul-
tiple linear regression analysis revealed that serum cystatin C 
(=0.360, t=2.311, p=0.026) and hemoglobin A1c (=0.271, t=2.143, 
p=0.038) were the independent predictors of the Gensini score 
(Table 3). ROC curve analysis (Fig. 2) revealed that serum cystatin 
C level of 1111 ng/mL has a 67% sensitivity and 75% specificity 
for estimating multivessel CAD [p=0.017, area under the curve 
(AUC): 0.740, 95% CI: 0.568–0.911].
Discussion 
In the present study, we investigated the diagnostic value of 
serum cystatin C and NGAL levels for the prediction of CAD se-
verity in type 2 diabetic patients. Our results showed that serum 
Anatol J Cardiol 2016; 16: 756-61
Table 1. Demographics and baseline clinical parameters of the patients
  All patients  Severe   Non-severe P 
   CAD (n=26) CAD (n=26)
Age, years 65.7±8.6 64.3±8.4 66.5±9.6 0.08
Gender, male/female  32/20 19 / 7 13/13 0.15
BMI, kg/ m2 29.2±3.9 29.2±4.2 29.3±3.6 0.91
Smoking, % 21.2  30.8 11.5 0.17
Hypertension, % 88.5  88.5 88.5  1.00
Hyperlipidemia, % 69.2  73.1 65.4 0.76
Gensini score  23 (5–51) 51 (29–69) 4.75 (1–10) <0.001
Laboratory findings
HbA1c, % 7.41±1.45 7.66±1.47 7.18±1.43 0.24
BUN, mg/dL  18.63±6.86 19.92±8.28 17.34±4.89 0.18
Scr, mg/dL  0.86±0.17 0.92±0.15 0.80±0.17 0.006
eGFR, mL/min /1.73 m2 88.32±18.70 82.96±19.50 93.69±18.75 0.049
Hemoglobin, g/dL  13.76±1.40 13.81±1.56 13.72±1.25 0.80
Total-C, mg/dL 188.81±35.36 190.66±31.80 186.52±40.22 0.73
LDL-C, mg/dL 112.00±30.55 116.44±31.10 107.17±29.86 0.30
HDL-C, mg/dL 40.89±9.64 41.15±10.59 40.61±8.76 0.86
Triglycerides, mg/dL 147 (119–196) 150 (132–192) 129 (99–197) 0.20
Medications, %
Insulin  23.1 34.6 11.5 0.10
Oral antihypoglycemic 
agents 86.5 80.8 92.3 0.42
ACEI 28.8 23.1 34.6 0.54
ARB  36.8 42.3 30.8 0.56
CCB  32.7 38.5 26.9 0.55
β-blockers 53.8 61.5 46.2 0.40
Statins  57.7 53.8 61.5 0.78
Acetylsalicylic acid  59.6 65.4 53.8 0.57
Warfarin  3.8 3.8 3.8 –
Nitrates 11.8 15.4 7.7 0.67
Data are presented as mean±standard deviation, median with 25th and 75th percen-
tiles, or number and frequencies where indicated 
ACEI - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blocker; 
BMI - body mass index; BUN - blood urea nitrogen; C - cholesterol; CAD - coronary 
artery disease; CCB - calcium channel blocker; eGFR - estimated glomerular filtration 
rate; HbA1c - hemoglobin A1c; HDL-C - high-density lipoprotein cholesterol; LDL-C - 
low-density lipoprotein cholesterol; Scr - serum creatinine 
Student’s t-test or Mann–Whitney U Test and chi-square test were used for statistical 
analyses
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Figure 1. Comparison of cystatin C levels according to the vessel 
score. Serum cystatin C concentrations were increased across the 
vessel score (P=0.03). Posthoc tests revealed significant differences 
in cystatin C levels between no-vessel and three-vessel disease 
(P=0.016) and between one-vessel and three-vessel disease (P=0.020)
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cystatin C levels were higher in multivessel CAD and strongly 
predicted the disease severity. However, we did not observe 
any association between serum NGAL levels and the severity of 
CAD. To our best of knowledge, this is the first study investigating 
cystatin C and NGAL levels simultaneously in regard to coronary 
atherosclerotic burden in type 2 diabetic patients.
Cardiovascular diseases (CVDs) are the leading causes of 
mortality and morbidity in DM, and diabetic patients have more 
extensive disease than patients having other risk factors for CAD 
(1, 2). The increased prevalence of accompanying disorders such 
as hypertension and dyslipidemia also contribute to the higher 
CVD event rates in diabetes (20). The increased CVD risk in type 
2 DM can be explained by a complex combination of various 
traditional and nontraditional risk factors. The pathogenesis of 
CVD in diabetes includes epigenetic, intracellular, and metabolic 
changes resulting in oxidative stress, inflammation, and endothe-
lial dysfunction (9). In type 2 DM, chronic toxicity of glucose and 
free fatty acids is related with the induction of inflammatory pro-
cesses within various tissues, particularly in vascular wall (10). 
Moreover, a low-grade inflammation plays an important role in 
the pathogenesis of the insulin resistance (21). Due to this strict 
relation, different biochemical markers reflecting inflammatory 
processes are used for screening CVD risk in diabetics.
It has been shown that impaired renal functions are related 
with increased all-cause and cardiovascular mortality, adverse 
cardiovascular events, and hospitalization rate in a large, com-
munity-based population (22). NGAL and cystatin C have been 
proven as biomarkers of renal injury and functions and accepted 
being accurate parameters for estimating renal functions (4, 12). 
These biologic substances also have important contributions 
to inflammatory processes involved in atherosclerosis as dis-
cussed earlier (3–6, 13–15).
In recent clinical trials, cystatin C has been found to be rela-
ted with severity of CAD and a predictor of mortality and adverse 
cardiovascular events in patients with acute coronary events 
(23–25). Niccoli et al. (13) evaluated 70 patients with normal re-
nal functions and stable CAD and reported a relation between 
increased cystatin C and coronary atherosclerotic burden. How-
ever, in the study of Doğaner et al. (26), which included 88 non-
diabetic patients with an eGFR of >60 mL/min/1.73 m2, cystatin 
C levels were lower in patients with CAD, and they showed an 
inverse association between number of involved coronary ar-
tery and cystatin C levels. They speculated that higher levels of 
cystatin C might indicate the presence of vulnerable plaques. 
That study, however, did not show the plaque morphology. They 
also found no correlation between cystatin C and eGFR in their 
study population. Subsequently, in two clinical trials including 
both diabetic and non-diabetic stable CAD patients without renal 
dysfunction (eGFR of >60 mL/min/1.73 m2), cystatin C was cor-
related with severity of CAD quantified by Gensini score (14, 27). 
Qing et al. (16) provided that cystatin C levels were elevated in 
asymptomatic CAD in metabolic syndrome patients. They 
demonstrated positive correlations between cystatin C and num-
ber of diseased vessel and the Gensini score, and they found cys-
tatin C to be an independent predictor of CAD severity calculated 
by Gensini score. In this point, our results are in agreement with 
those studies demonstrating a close relation between cystatin C 
and severity of CAD. We showed that patients with multivessel 
disease and those with higher Gensini score had also increased 
serum cystatin C levels. In our study, there was a positive and 
modest correlation between cystatin C levels and the Gensini 
Table 2. Cystatin C and NGAL concentrations according to extent and severity of coronary artery disease
  Vessel score   Gensini score 
 Single-vessel Multi-vessel P Lower gensini score Higher gensini score P
Serum cystatin C, ng/mL 977 (599–1114) 1260 (953–1640) 0.017 929 (569–1156) 1114 (948–1567) 0.009
Serum NGAL, ng/mL 92 (60–133) 95 (65–152) 0.64 101 (63–139) 92 (62–143) 0.69
NGAL - neutrophil gelatinase-associated lipocalin. Mann–Whitney U test was used for statistical analyses
Table 3. Multivariate linear regression analysis model to investigate 
independent predictors of Gensini score
Variable β T P 95% CI
Age  0.230 1.500 0.141 (-0.264–1.799)
Gender 0.155 1.154 0.255 (-6.784–24.920)
Smoking 0.104 0.684 0.498 (-14.188–28.745)
Hypertension -0.136 -1.074 0.289 (-34.878–10.639)
Hyperlipidemia  0.083 0.655 0.516 (-10.710–21.005)
HbA1c 0.271 2.143 0.038 (0.316–10.370)
Cystatin C 0.360 2.311 0.026 (0.002–0.330)
eGFR  0.005 0.032 0.974 (-0.412–0.425)
CI - confidence interval; eGFR - estimated glomerular filtration rate; HbA1c - hemo-
globin A1c
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Figure 2. Receiver operating characteristics curve analysis to find out 
predictive values of cystatin C levels in estimating multivessel CAD 
(P=0.017, AUC: 0.740, 95% CI: 0.568–0.911)
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score and linear regression analysis revealed cystatin C as an 
independent predictor of the Gensini score. Furthermore, in our 
study, AUC of ROC analysis was 0.740. It was reported as 0.622 by 
Qing et al. (16) and 0.588 by Wang et al. (27). This indicates that 
cystatin C as a sole marker had a higher predictive value in our 
study. Nevertheless, our AUC value indicates that there could be 
some additional unknown predictors affecting atherosclerotic 
burden in this cohort, supporting the idea that atherosclerosis 
is a multifactorial and complex disease. When evaluating renal 
functions of the diabetic patients, the cut-off value of 1111 ng/
mL can be an acceptable level to effectively identify severe CAD. 
Serum NGAL has been shown to be elevated in a variety of CAD 
such as coronary ectasia (28), coronary slow flow phenomenon 
(29), and unstable coronary syndromes, including acute myocar-
dial infarction (30, 31). However, the role of NGAL in predicting 
severity of stable CAD has not yet been clearly elucidated. Zo-
grafos et al. (7) evaluated 73 stable CAD patients (21 with diabe-
tes) and reported that serum NGAL level was modestly corre-
lated (r=0.356) with Gensini score. In our study, however, serum 
NGAL levels were not related with presence or severity of stable 
CAD in diabetic patients. 
To our knowledge, there have been no data regarding simulta-
neous measurements of cystatin C and NGAL for the evaluation 
of stable CAD in either diabetic or non-diabetic population. Still, 
possible mechanisms underlying the link between cystatin C and 
CAD need to be described. It can simply be argued that renal 
mechanisms are responsible for this relation. However, in our 
diabetic cohort, mean serum creatinine values were within the 
normal range, but mean eGFR value was relatively low; this sug-
gested slightly impaired kidney functions. Patients with severe 
CAD had higher serum creatinine, lower eGFR values, and higher 
cystatin C levels. Importantly, cystatin C remained as a predictor 
for CAD severity, even after adjustment for eGFR value. Hence, 
we cannot exactly explain the association between cystatin C 
and CAD severity via solely impaired kidney dysfunction, which 
predicts severe cardiovascular outcomes. Based on previous 
clinical trials demonstrating positive correlations between se-
rum cystatin C and highly sensitive C reactive protein and fibri-
nogen (14, 27), it could be speculated that cystatin C participates 
in inflammatory processes that are involved in coronary athero-
sclerosis. Further clinical investigations with larger cohorts are 
needed to explain exact mechanisms. 
Study limitations
Ours was a single-center and relatively small-sized study. We 
did not determine relations between CAD and serum NGAL and 
cystatin C levels after graduating the patients into different stages 
of nephropathy. Use of complementary biomarker(s) of inflamma-
tion and considering the duration of DM which may affect levels of 
the markers could render our results more contributory. Ultimately, 
in biomarker assays racial/ethnic differences should be regarded, 
and our results may not generalize to the all diabetic population.
Conclusion
Our fi ndings showed that serum cystatin C levels, but not 
NGAL levels, were significantly associated with severity of sta-
ble CAD in type 2 diabetic patients. Serum cystatin C levels could 
be a marker of coronary atherosclerosis independent of kidney 
function. We believe that our study may inspire further trials to 
investigate cystatin C in this regard.
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